cyclophosphamide + prednisone + lenalidomide

Cyclophosphamide + prednisone + lenalidomide is a three-drug combination regimen, often referred to as the REP regimen, used primarily in the treatment of multiple myeloma, especially in relapsed or refractory cases. Cyclophosphamide is an alkylating agent that interferes with DNA replication and induces cell death. Prednisone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties. Lenalidomide is an immunomodulatory drug (IMiD) that exerts direct antitumor effects, inhibits angiogenesis, modulates the immune microenvironment by enhancing T-cell and natural killer cell activity, and suppresses cytokine production. The combination has demonstrated synergistic efficacy in patients who are refractory to other treatments such as lenalidomide or bortezomib alone[1][3][4][6]. This regimen has shown high response rates and improved progression-free survival compared to two-drug regimens[1][4][6].

Brand names

Revlimid (for lenalidomide)Endoxan (for cyclophosphamide)

Other names

REP regimen